Terumo : Appoints Three Associates as the Newest Terumo Fellow
June 06, 2022 at 09:12 pm EDT
Share
June 07, 2022
TOKYO, JAPAN - June 7, 2022 - Terumo Corporation (TSE: 4543) today announced that it has appointed three associates as the newest "Terumo Fellow". Terumo instituted the Terumo Fellow program to recognize associates who have made outstanding contributions leading to innovation in healthcare, as well as promoting the advancement of technology, research, clinical, and regulatory affairs of the Terumo Group. Terumo Fellows are also nominated for their contribution to transmit Terumo's core technologies and serve as an inspiration for all associates. Since the establishment of the Terumo Fellow program in 2016, 9 associates have been appointed as a Terumo Fellow.
Terumo defines "Advancement of healthcare" and "Enhancement of patients' QOL" as its purpose. To realize the advancement of healthcare, Terumo will continue to accelerate activities in the fields of technology, research, clinical and regulatory affairs, to further contribute to healthcare around the world.
Terumo Fellows
Tetsuya Ooyauchi
General Manager, Technology Coordination Office
Achievements:
・ Development of pen-type insulin injection needles used for diabetes treatment.
・ Development of diabetes-related products, disposable medical devices, ME devices and a wide range of products.
Akio Kutsuzawa
General Manager, ME R&D, Cardiac and Vascular Company
Achievements:
・ Realizing commercialization and mass production of the controller of extracorporeal membrane oxygenation (ECMO) system.
・ Engaged in a wide range from elemental technology development to commercialization. Development and commercialization of many ME devices that can be used in combination with disposable medical devices.
Joseph Gulachenski
Senior Director, R&D, MicroVention, Inc.
Achievements:
・ Led the development of more than 30 medical devices for neurovascular treatment.
・ Contributed to MicroVention to evolve from a "coil company" to expand beyond cerebral aneurysms to a "neurovascular company" including devices to treat ischemic stroke, carotid artery disease, and neurovascular malformations.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Terumo Corporation published this content on 07 June 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 07 June 2022 01:11:08 UTC.
Terumo Corporation specializes in the design, manufacturing and marketing of medical products and equipments. Net sales break down by family of products as follows:
- cardiac surgery devices (53.5%);
- medical products for hospitals (28.6%): medical devices, nutritional additives, oxygen, medical measuring devices (thermometers, tensiometers, glucometers, etc.), etc.;
- sanguine transfusion equipments (17.9%).
Net sales break down geographically as follows: Japan (32.9%), America (29.5%), Europe (19.6%), China (7.4%) and other (10.6%).
TERUMO CORPORATION 
